What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published

Canakinumab for the Patient With Difficult-to-Treat Gouty Arthritis: Review of the Clinical Evidence

 

Abstract

 

Many patients with gouty arthritis experience frequent flares and have comorbidities that may limit their anti-inflammatory treatment options for acute flare management. For patients with contraindications to both NSAIDs and/or colchicine, treatment options are particularly limited, and there is an unmet medical need in this subgroup of patients.

Continue Reading

 

 

REFERENCE:

Thomas Bardin, Canakinumab for the Patient With Difficult-to-Treat Gouty Arthritis: Review of the Clinical Evidence, Joint Bone Spine, Volume 82, Supplement 1, 2015, Pages eS9-eS16,
ISSN 1297-319X,
https://doi.org/10.1016/S1297-319X(15)30003-8.

 

 

INDICATIONS:

Gouty arthritis Ilaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

Periodic Fever Syndromes: Ilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:

Cryopyrin-Associated Periodic Syndromes (CAPS) Ilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) in adults, adolescents and children aged 2 years and older with body weight of 7.5 kg or above, including: • Muckle-Wells syndrome (MWS), • Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA), • Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial coldurticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash. Tumour necrosis factor receptor associated periodic syndrome (TRAPS) Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS). Hyperimmunoglobulin D syndrome (HIDS)/ mevalonate kinase deficiency (MKD) Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/ mevalonate kinase deficiency (MKD).

Familial Mediterranean Fever (FMF) Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF) in patients in whom colchicine is contraindicated, is not tolerated, or does not provide an adequate response despite the highest tolerable dose of colchicine. Ilaris can be given as monotherapy or in combination with colchicine.

Ilaris is also indicated for the treatment of:

Still’s disease Ilaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.